新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 老年性痴呆 » 卫材与百健艾迪合作开发阿尔茨海默氏药物

卫材与百健艾迪合作开发阿尔茨海默氏药物

来源:生物谷 2014-03-06 16:02

2014年3月6日讯 /生物谷BIOON/ --卫材(Eisai)和百健艾迪(Biogen Idec)3月5日联合宣布,双方已签订合作协议,开发和商业化卫材研发管线中的2种阿尔茨海默氏症(AD)药物:E2609和BAN2401。同时,该项协议也为卫材提供了选择权,共同开发和商业化百健艾迪管线中的2种AD药物:抗β淀粉样蛋白(Aβ)抗体BIIB037和一种抗tau蛋白的单克隆抗体。

E2609是一种β位点淀粉样前体蛋白裂解酶(BACE)抑制剂,BAN2401则是一种Aβ抗体,这2种药物均有望减少AD患者大脑中的Aβ斑块,并阻止新斑块的形成,具有改善患者症状和抑制病情恶化的潜力。

在E2609和BAN2401的联合开发中,卫材将领导研究的实施和监管,同时将寻求全球范围内的上市许可申请。而在主要市场,如美国和欧盟,卫材将和百健艾迪联合销售药物。百健艾迪将支付一笔预付款和固定金额的开发、审批、商业化里程碑款项。该协议还包括双方在日本联合开发和商业化活动的额外一次性付款。

关于E2609

E2609是一种实验性新一代口服阿尔茨海默氏症(AD)候选药物,由卫材内部发现,被认为能够抑制Aβ生成中的一种关键酶BACE。通过抑制BACE,E2609能够减少大脑中的Aβ蛋白,具有改善症状和延缓疾病进展的潜力。目前,该药正在准备进入II期临床。

关于BAN2401

BAN2401是一种人源化单克隆抗体,由卫材和BioArctic Neuroscience公司之间的战略研究联盟开发。BAN2401被认为能够选择性结合、中和并消除可溶性、有毒性Aβ的聚集。因此,BAN2401具有免疫调节的作用,具有抑制病情恶化的潜力。目前,该药正处于II期临床。

关于BIIB037

BIIB037是一种抗Aβ人单克隆抗体,由百健艾迪从Nurimmune公司授权获得。据认为,BIIB037能够结合并消除AD患者大脑中的毒性淀粉样斑块,从而潜在地抑制疾病的恶化。目前,该药正处于Ib期临床。

英文原文:Eisai and Biogen Idec Enter Collaboration to Develop and Commercialize Alzheimer’s Disease Treatments

- Agreement to Enhance R&D Capabilities and Pipeline Aimed at Creating New Therapies to Suppress Alzheimer’s Disease Progression -

TOKYO & CAMBRIDGE, Mass.Eisai Co., Ltd. (TSE: 4523) and Biogen Idec (NASDAQ: BIIB) announced today that they have entered into a collaboration to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease (AD), E2609 and BAN2401. The agreement also provides Eisai with an option to jointly develop and commercialize two of Biogen Idec’s candidates for AD, the anti-amyloid beta (Aβ) antibody BIIB037 and an anti-tau monoclonal antibody.

The collaboration initially will be centered on the co-development and co-commercialization of Eisai’s two candidates: E2609, a β-site amyloid precursor protein cleaving enzyme (BACE) inhibitor, and BAN2401, an anti-Aβ antibody. These candidates have the potential to reduce Aβ plaques that form in the brains of patients with AD and to stop the formation of new plaques, potentially improving symptoms and suppressing disease progression.

Eisai will serve as the operational and regulatory lead in the co-development of E2609 and BAN2401 and will pursue marketing authorizations for both compounds worldwide. In major markets, such as the United States and the European Union, Eisai and Biogen Idec will also co-promote the products following marketing approval. Both companies will share overall costs, including research and development expenses, with Eisai booking all sales for E2609 and BAN2401 and with profits to be split between the companies.

Biogen Idec will provide Eisai with an upfront payment and a fixed amount of development, approval and commercial milestone payments. The agreement also includes options for Eisai to receive an additional one-time payment from Biogen Idec related to joint development and commercialization activities in Japan.

“This collaboration is a natural fit with our mission to develop therapies for patients with severe neurodegenerative diseases. Eisai’s candidates have demonstrated compelling early data and complement our AD research while extending our pipeline in this critical area,” said George A. Scangos, Ph.D., chief executive officer of Biogen Idec. “Eisai is a pioneer in successfully developing and commercializing AD treatments. This history, combined with their strong scientific heritage, geographical reach and unwavering commitment to the AD community, makes Eisai an excellent collaboration partner to help drive our mission.”

Eisai Co., Ltd. President & CEO Haruo Naito added, “There exists an urgent need to develop AD therapies that suppress disease progression in order to effectively alleviate both the emotional burden of suffering and uncertainty experienced by patients and their families, as well as the financial burden on overall society in terms of the huge costs of nursing and patient care. Eisai remains deeply focused on the development of such therapies based on the knowledge and experience it has accumulated through its development of the anti-AD agent Aricept?. Through our collaboration with Biogen Idec, a company that specializes in neurodegenerative diseases, I believe we will be able to further enhance our existing R&D capacities for developing next-generation AD treatments, thereby accelerating the development of promising therapies and increasing the benefits provided to patients with AD worldwide.”

About E2609

E2609, discovered in-house by Eisai, is an investigational next-generation oral candidate for the treatment of AD that is believed to inhibit BACE, a key enzyme in the production of Aβ. By inhibiting BACE, E2609 decreases Aβ proteins in the brain, potentially improving symptoms and slowing disease progression. Currently, E2609 is undergoing preparations to enter Phase II clinical trials.

About BAN2401

BAN2401 is a humanized monoclonal antibody that is the result of a strategic research alliance between Eisai and BioArctic Neuroscience AB to identify a potential immunotherapy for AD. BAN2401 is believed to selectively bind to, neutralize and eliminate soluble, toxic Aβ aggregates that are thought to contribute to the neurodegenerative process in AD. As such, BAN2401 has the potential to have an immunomodulatory effect that may suppress the progression of the disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of AD pursuant to an agreement concluded with BioArctic Neuroscience AB in December 2007. Currently, the compound is undergoing Phase II clinical trials.

About BIIB037

BIIB037 is an anti-Aβ human monoclonal antibody that is currently under investigation by Biogen Idec as a treatment for AD under a license from Neurimmune. It is believed that BIIB037 binds to and eliminates the toxic amyloid plaques that form in the brains of patients with AD, thereby potentially suppressing the progression of the disease. BIIB037 is currently undergoing a Phase Ib clinical trial.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库